Losartan-based therapy vs atenolol-based therapy in essential hypertension with signs of left ventricular hypertrophy†
| Outcomes | Losartan | Atenolol | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| †Abbreviations defined in Glossary; RRR, NNT, and CI calculated from data in article. | ||||
| ‡Cardiovascular mortality, stroke, and myocardial infarction. | ||||
| Composite end point‡ | 11% | 13% | 12% (2 to 22) | 64 (36 to 418) |
| Stroke | 5% | 7% | 24% (11 to 36) | 61 (42 to 140) |
| New-onset diabetes | 6% | 8% | 24% (12 to 36) | 52 (35 to 108) |